Shanghai Leado Pharma

Shanghai Leado Pharma is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of innovative small molecule therapeutics. The company leverages its proprietary targeted protein degradation (TPD) platform, including PROTAC technology, to address unmet medical needs in oncology and metabolic diseases. Its lead candidate, LD-001, is an orally bioavailable androgen receptor degrader currently undergoing clinical evaluation for the treatment of metastatic castration-resistant prostate cancer. Leado Pharma aims to overcome drug resistance associated with traditional inhibitors by utilizing the body's natural protein disposal system. The company's pipeline also includes several discovery-stage programs targeting various solid tumors and hematological cancers.